American Association for Cancer Research


Bookmark and Share
Chemical Systems Biology 2012


Abstract submissions are no longer being accepted for this conference. The abstract submission deadline was Tuesday, May 15.


Only those abstracts that have been reviewed and selected by the Conference Co-Chairpersons may be presented. All individuals listed as ABSTRACT PRESENTERS were notified of acceptance or rejection by email approximately three weeks after the abstract submission deadline. Notices and instructions were sent to the email address provided at the time of abstract submission. If an abstract is not selected for presentation, the presenter may request a full refund of the registration fee by contacting the AACR Meetings Department at


Individuals planning on presenting an abstract at this conference are encouraged to register and make a room reservation at the conference hotel as early as possible. If an abstract is not accepted for presentation at the conference, the presenter may request a full refund of the registration fee and may cancel his/her room reservation at no charge up to three days before the scheduled arrival date. For additional information, please visit the registration and accommodations and travel webpages.


Abstracts selected for presentation during the conference will be printed in the Conference Proceedings from submitted material. Every effort will be made to reproduce the content of the abstracts as submitted, except in certain circumstances where changes may be made to comply with AACR style. Abstract titles and authors are posted below (only titles and authors, no data will be posted online before or after the conference). For those abstracts that have been accepted for poster presentation, poster boards will be 4 feet high and 8 feet across (1.22m x 2.44m) and AACR will provide poster numbers and pushpins. See a sample poster layout. For programs that include short talks selected from the abstract submissions, instructions will be sent to the ABSTRACT PRESENTERS with the date, time, and format for those presentations.


Once an abstract has been submitted, it may be withdrawn only by written request from the ABSTRACT PRESENTER. The request may be sent by fax to (215) 599-0111 or email to and must be received at least 30 days prior to the start of the conference.

Thursday, June 28
1:30 p.m.-3:30 p.m.

    Abstract titles and authors only

  • A chemical screen in Tuberin-null cells identifies potential therapies for mTORC1 hyperactive cancers. Doug Medvetz.
  • A cooperative molecular response to combined mTOR/HDAC inhibition revealed by transcriptional co-expression analysis. John Kyle Simmons, Beverly A Mock, Aleksandra Michalowski, Jyoti Patel, Bih-Rong Wei, R Mark Simpson, W Michael Kuehl, Shuling Zhang, Ke Zhang, Ola Landgren.
  • A model of HGF and EGF dual ligand stimulation in ACHN cells constructed with the aid of a novel model merging heuristic. Andrew L Matteson.
  • A signaling pathway rationale for the design of combination therapies for cancer. Paola Vera-Licona, Andrei Zinovyev, Eric Bonnet, Inna Kupperstein, Olga Kel-Margoulis, Alexander Kel-Margoulis, Thierry Dubois, Gordon Tucker, Emmanuel Barillot.
  • A systems biology approach to elucidating the consequences of complex ternary interactions of heparin, FGF ligands, and FGF receptor on downstream signaling in NSCLC cells. Diana H Chai, Jaeyeon Kim, Jannik Vollmer, Andrijana Radivojevic, Jitendra Kanodia, Marco Muda, Birgit Schoeberl.
  • An ex vivo drug sensitivity resistance testing (DSRT) platform identifies putative patient-specific molecular drivers of adult AML. Tea Pemovska, Agnieszka Szwajda, Jing Tang, Laura Turunen, Jonathan Knowles, Caroline Heckman, Kimmo Porkka, Olli Kallioniemi, Tero Aittokallio, Krister Wennerberg, Bhagwan Yadav, Evgeny Kulesskiy, Mika Kontro, Riikka Karjalainen, Muntasir Mamun Majumder, Naga Poojitha Kota Venkata, Samuli Eldfors, Henrik Edgren.
  • Cells decide between quiescence and proliferation upon exit from mitosis. Sabrina Leigh Spencer, Feng-Chiao Tsai, Tobias Meyer.
  • Considering alternate signaling mechanisms models in extrinsic apoptosis using programmatic modeling approaches. Carlos F Lopez, Jeremy L Muhlich, John J Bachman, Peter K Sorger.
  • Discovery of driver-type therapeutic targets to reverse glucocorticoid resistance in T-ALL. Jiyang Yu, Ericah Piovan, Maria Sol Flaherty, Jose Silva, Adolfo Ferrando, Andrea Califano.
  • Dissecting gatekeeper BCR-ABL-specific drug synergy by an integrated systems chemical biology approach. Uwe Rix, Georg E. Winter, Scott M. Carlson, Karoline V. Gleixner, Florian Grebien, Manuela Gridling, Andre Müller, Martin Bilban, Jacques Colinge, Peter Valent, Keiryn L. Bennett, Forest M. White, Giulio Superti-Furga.
  • Dissecting signaling transduction network to infer master regulators of non small cell lung cancer. Mukesh Bansal, Michael Peyton, Manjunath Kustagi, Luc Girard, Klarisa Rikova, Michael Comb, Michael White, John Minna, Andrea Califano.
  • Drug-gene-microRNA networks in therapeutic and biomarker development. Jian Zhu.
  • High-content screen for inhibitors of cell migration in cancer metastasis using adenoviral knock-down. Remko de Pril, Annemarie Lekkerkerker, Desire van Steenhoven, Ilhem Maghrani, Tim Perera, Janine Arts, David Fischer, Richard Janssen.
  • High-throughput small molecule screening of genetically diverse glioblastoma stem cells. Garth W Strohbehn, Jiangbing Zhou, Michael Fu, Toral R Patel, Joseph M Piepmeier, W. Mark Saltzman.
  • In silico designed covalent peptidomimetic inhibitors (KPT-SINE) of CRM1 modulate tumor suppressor protein nuclear export and induce apoptosis in cancer cells. William T Senapedis, Erkan Baloglu, Doriana Froim, Dilara McCauley, Yuh Min Chook, Michael Kauffman, Sharon Shacham, Yosef Landesman, Ori Kalid, Sharon Shechter, Jean Richard St Martin, Trinayan Kashyap, Boris Klebanov, Louis Plamondon, Vincent Sandanayaka.
  • Integrated analysis of molecular and metabolomic data to identify drug resistance mechanisms in lung cancers. Anand S Merchant, Natalie Fedorova Abrams, Eric A Stahlberg, Zoe Weaver.
  • Investigating combinatorial ligand addiction provides insights into rational drug combinations in cancer therapy. Emily A Pace, Ulrik B Nielsen, Birgit Schoeberl, Diana H Chai, Anand Parikh, Ashish Kalra, Shinji Oyama, Bryan Johnson, Gege Tan, Aaron Fulgham, Raghida Bukhalid.
  • Investigating the differential regulation of poly (ADP-ribose) polymerases in cancer. Kristin Krukenberg, Timothy Mitchison.
  • Mapping of chemical-genetic interactions in breast cancer reveals a mechanism of resistance to PI3K inhibitors. Markus K Muellner, Iris Z Uras, Bianca Gapp, Sebastian M Nijman.
  • Mechanistic insight into mitochondrial role in prostate cancer metastasis and keratin modulation revealed through the BERG INTERROGATIVE BIOLOGY platform. Rangaprasad Sarangarajan, Viatscheslav Akmaev, Vivek K Vishnudas, Niven Narain.
  • Mechanistic investigation of the anti-cancer and anti-hyperlipidemia effects of Gynostemma triterpenoids using systems biology approach. William Chi Shing Tai, Wing Yan Wong, Jen Fu Chiu, Wen Luan Wendy Hsiao.
  • Molecular Detection of Prostate-Specific Membrane Antigen in Canine Prostate Carcinoma Cells. Lisa Y Wu, Tiancheng Liu, Bernard Vanwie, William C Davis, Clifford E Berkman.
  • Network analysis of retroviral and transposon mutagenesis sites in B cell lymphoma converges on MyD88 pathway. Samuel Lifton, Alicia Olivier, Adam Dupuy, Wendy Dubois, Linda Wolff, Siegfried Janz.
  • Network modeling of epithelial-to-mesenchymal transition in liver cancer metastasis. Steven N Steinway, Hien Dang, Wei Ding, Carl B Rountree, Reka Albert.
  • Novel chemical systems biology approach with the BERG INTERROGATIVE BIOLOGY® platform provides a window into hallmark shift in cancer metabolism. Niven R Narain, Vivek K Vishnudas, Viatscheslav R Akmaev, Rangaprasad Sarangarajan.
  • Novel ursolic acid derivatives with potent antitumor activity. Ana S. Leal, Jorge A.R. Salvador, Jing Yongkui.
  • Predicting drugs effect on transcription factor activity by regulatory network analysis of drug perturbed cellular states. Yao Shen, Mariano Alvarez, Sergey Pampou, Jorida Coku, Andrea Califano.
  • Reactivation of p53 using genetic and chemical approaches to disrupt p300/CH1-HPV16 E6 interaction in HPV-associated head and neck squamous cell carcinoma. Xiujie Xie, Longzhu Piao, Tizhu Su, Manchao Zhang, Theodoros Teknos, Quintin Pan.
  • Reversal of glucocorticoid resistance by AKT inhibition in T-ALL. Erich Piovan, Jules Meijerink, Carlos Cordon-Cardo, Andrea Califano, Adolfo Ferrando, Jiyang Yu, Valeria Tosello, Castillo Mireia, Elisabeth Paietta, Janis Racevskis, Jakob Rowe, Martin Tallman.
  • Role of dermcidin in tomorigenesis of skin cancers. Beatriz A Sangiuliano, Marcela Nancy Perez, Aline Cadurin, Andrew Aguiar, Dayson F Moreira, Jose E Belizario.
  • SNAIL inhibitor GN-25 induces MET through Global Reprograming of EMT Network Genes: a Systems and Network Analysis. Asfar S Azmi, Ramzi M Mohammad, Fazlul H Sarkar.
  • Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach. Jaeyeon Kim, Eliel Bayever, Peter Laivins, Clet Niyikiza, Ulrik Nielsen, Jonathan Fitzgerald, Ashish Kalra, Milind Chalishazar, Stephan Klinz, Nancy Paz, Bart Hendriks, Daryl Drummond, Dmitri Kirpotin, Victor Moyo.
  • The receptor tyrosine kinase layer of breast cancer cell lines is predictive of the response to therapeutic drugs. Mario Niepel, Marc Hafner, Emily Pace, Birgit Schoeberl, Peter K Sorger.
  • Time-Resolved Luminescence Detection of Spleen Tyrosine Kinase Activity Through Terbium Sensitization. Andrew M Lipchik, Laurie L Parker.
  • Two dimensional chemical interrogation of oncogenic systems and multi-omics integration of signatures reveals novel signaling pathways involved in the pathophysiology of cancer. Vivek K Vishnudas, Min Du, Viatscheslav Akmaev, Rangaprasad Sarangarajan, Niven R Narain.
  • Visualizing the dynamic and heterogeneous responses of single cells to inhibitors of the growth factor signaling network. John Albeck, Yin P Hung, Gregory Leya, Gary Yellen, Gordon Mills, Joan Brugge.